

Title: **Melanoma Treatment**

Reference Number: RDF1299-23

Date of Response: 13/03/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

I am researching the usage of Pembrolizumab for the treatment of Melanoma.

How many patients have you treated with Pembrolizumab in the three months from October to December 2022 for:*

- *Melanoma - any stage*
- *Melanoma - Stage IIb/IIc*
- *Melanoma - Stage III*
- *Melanoma – Metastatic*

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

	<i>RDUH Trust response. No. of patients treated**</i>
<i>Melanoma – any stage</i>	60
<i>Melanoma – Stage IIb/IIc</i>	≤ 5
<i>Melanoma – Stage III</i>	29
<i>Melanoma – Metastatic</i>	25

** Latest data available September to November 2022*

*** 5 patients have no stage grouping*